Salute e Benessere

IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024

Aggregatedpresentationbydayandbymarket Statement of transactions in own shares from June 3 to June 7, 2024 Name of issuerIdentificationcodeof issuer (Legal Entity Identifier)Day of transactionIdentificationcodeof financial instrumentAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares *Market (MIC Code)IPSEN...
Nasdaq GlobeNewswire
11/06/2024

Global Pet Furniture Market to Hit $10.65 billion by 2031: Coherent Market…

Market Dynamics: Market Dynamics: The growth of the global pet furniture market is primarily driven by rising pet humanization as well as increasing number of nuclear & blended families globally. According to the US Pet Owners Survey 2021 by the American Pet Products Association (APPA), around 90.5 million households inthe United Statesowned a pet as of 2021. Pets are considered as family members by majority of owners, which has increased the spending towards high-quality pet...
PR Newswire
11/06/2024

Osteotec and TriMed, Inc., agree distribution partnership for the Osteotec…

This collaboration, launched in February, signifies a major advance in Osteotec's mission to extend the reach of its product portfolio across the United States, with a special focus on delivering its flagship product, the Osteotec Silicone Finger Implant. This collaboration, launched in February, signifies a major advance in Osteotec's mission to extend the reach of its product portfolio acrossthe United States, with a special focus on delivering its flagship product, the Osteotec Silicone...
PR Newswire
11/06/2024

Dunaliella Salina Market to Reach $69.60 Million by 2031--Exclusive Report by…

Dunaliella is a genus of the algae family Dunaliellaceae. Dunaliella salina is a unicellular, green, halophilic microalgae species generally found in environments with high salt concentrations. Dunaliella salina's rich nutritional profile of high-quantity antioxidants, along with a vast spectrum of vital phytonutrients, makes it an active ingredient in the nutritional supplements and cosmetics industries. Natural beta-carotene from Dunaliella salina contains pro-vitamin A, which is converted to…
PR Newswire
11/06/2024

Flow Cytometry Market Surges to $10.3 Billion by 2032, Driven by 9.2% CAGR…

Browse in-depth TOC on "Flow Cytometry Market" Browse in-depth TOC on "Flow Cytometry Market" 713 - Tables 56 - Figures 559 - Pages Innovative Advancements Propel Growth In the dynamic global flow cytometry market, the introduction of cutting-edge technological advancements propels market expansion by catering to the demand for enhanced workflow efficiency and superior performance. Key players are continually innovating to develop and commercialize advanced flow cytometry...
PR Newswire
11/06/2024

Pfizer Reflects on 175-Year Global Legacy and Decades of Regional Breakthroughs

Patrick van der Loo, Regional President of Pfizer MERA, commented: "As we come together to mark this momentous milestone, today is an opportunity to acknowledge the endless global breakthroughs we have led over the past 175 years and the immense contributions that we have made to the regional medical landscape over the last 65 years. We are incredibly honored to partner with public sector leaders and to be strategic contributors in driving national healthcare agendas forward, bringing…
PR Newswire
11/06/2024

Blood Brain Barrier Market Untapped Growth Opportunities Analysis - Latest…

Request for Free Sample Pages: https://www.insightaceanalytic.com/request-sample/2527 Request for Free Sample Pages: https://www.insightaceanalytic.com/request-sample/2527 The Blood-Brain Barrier (BBB) market refers to the industry focused on developing, researching, and commercializing technologies, therapies, and strategies aimed at understanding, modifying, and interacting with the blood-brain barrier. The blood-brain barrier (BBB) is a selective permeability barrier that isolates...
PR Newswire
11/06/2024

Leo Cancer Care to Use Series C Financing to Grow Global Footprint

This investment highlights increasing confidence investors have in the team and the product, which is offering a "more human" way to administer radiation therapy to patients with a range of cancers. The unique upright patient positioning and CT imaging system, named Marie® after Nobel laureate and radioactivity research pioneerMarie Curie, utilizes a fixed radiation beam with patients rotated slowly and smoothly to different beam angles as treatment is administered. The...
PR Newswire
11/06/2024

ZINZINO AB (PUBL): Zinzino announces Serbia as next step in its global expansion

Market analysis shows that direct selling is popular among Serbian consumers and a natural way of selling for entrepreneurs seeking extra income. Digital commerce is growing rapidly, and more than two-thirds of the Serbian population use social media daily. Social selling combined with Zinzino's digital toolbox creates favorable conditions for their distributors to reach new customers in Serbia. Market analysis shows that direct selling is popular among Serbian consumers and a natural way of...
PR Newswire
11/06/2024

The 1000 Miglia 2024 has started

"The wait before the race is always nerve-wracking," said Andrea Vesco, in the hunt for his fourth consecutive victory at the 1000 Miglia, from the cockpit of the 1929 Alfa Romeo 6C SS Spider Zagato. "Let's hope it doesn't keep raining so we can pull down the top, but in any case once we get going I hope we settle into the race well as always." "The wait before the race is always nerve-wracking," said Andrea Vesco , in the hunt for his fourth consecutive victory at…
PR Newswire
11/06/2024

FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for…

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate shown to cause T regulatory (Treg) cell induction when dosed intranasally. At present, ten (10) na-SPMS patients have been dosed in an Intermediate-Sized Patient Population Expanded Access (ISPPEA) Program with clinically meaningful reduction in fatigue scores (MFIS) in 70% of patients, and stability of disease noted within six months in all ten patients. In addition, intranasal foralumab is currently being...
Nasdaq GlobeNewswire
11/06/2024

Cumulus Neuroscience to Partner with The Digital Medicine Society (DiMe) to…

Cumulus will participate in the DATAcc by DiMe Building the Business Case for Digital Endpoints project, which will convene leaders from across the field to establish shared industry benchmarks for evaluating the return on investment (ROI) of digital endpoints in the development of drugs, medical devices, and other regulated interventions. Outputs of the project will include a value framework, industry benchmarking tools, ROI forecasting models, and a modular template to support innovators…
PR Newswire
11/06/2024

Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9…

New sponsored testing program leverages Myriad's MyChoice Tests for patients with high-grade serous ovarian cancer Myriad Genetics, Inc.(NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. A new sponsored testing program leveraging Myriad's MyChoice HRD Plus and MyChoice CDx Plus Tests...
Nasdaq GlobeNewswire
11/06/2024

Nexstim Plc: Disclosure of Major Holdings according to Chapter 9, Section 10 of…

Company announcement, Helsinki, 11 June 2024 at 2 PM (EEST)Nexstim Plc: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act Nexstim Plc (NXTMH:HEX) (”Nexstim” or ”Company”) has received a notification pursuant to chapter 9, section 5 of the Securities Market Act from Kyösti Kakkonen on 10 June 2024.The notification is based on the amendment to the Securities Market Act effective April 19, 2024, requiring shareholders to notify the...
Nasdaq GlobeNewswire
11/06/2024

Ethyl Cyanoacetate Market worth $184 million by 2029 - Exclusive Report by…

140 – Tables60 – Figures200 – Pages 140 – Tables 60 – Figures 200 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34701457 Pharmaceuticals, by application, is expected to be the most significant Ethyl cyanoacetate Market segment during the forecast period. Pharmaceuticals has emerged as the fastest-growing end-use industry in the Ethyl cyanoacetate market because it serves as a crucial intermediate in the synthesis of various...
PR Newswire
11/06/2024

Augnito Announces Strategic Investment to Accelerate Digital Health Innovation

Augnito is at the forefront of SaaS innovation, providing state-of-the-art multi-lingual speech recognition, generative AI, and natural language processing technology to healthcare organizations worldwide. The company's suite of advanced voice-based solutions employs human-centric design principles to meet the evolving needs of both healthcare providers and patients. Augnito is at the forefront of SaaS innovation, providing state-of-the-art multi-lingual speech recognition, generative AI, and...
PR Newswire
11/06/2024

Proteomics Market to Reach $161.9 billion, Globally, by 2035 at 14.2% CAGR…

Prime determinants of growth Prime determinants of growth Proteomics focuses on the comprehensive analysis of proteins within a biological system. Unlike genomics, which examines the entirety of an organism's genetic material, proteomics delves into the intricate world of proteins, the functional workhorses of cells. It involves the large-scale study of the structure, function, and interactions of proteins, aiming to understand their roles in biological processes and disease states...
PR Newswire
11/06/2024

Alvotech and STADA add to Strategic Alliance through Denosumab Partnership

STADA assumes marketing license for Alvotech's proposed biosimilar referencing Prolia ® /Xgeva ®(denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle EastThis partnership for the osteoporosis and cancer-related molecule builds on the two company's existing strategic alliance in Europe. The first product launched through the alliance was Hukyndra ®, a high-concentration biosimilar to Humira ®(adalimumab) Extended...
Nasdaq GlobeNewswire
11/06/2024

HKBU-led research predicts humidity trends will result in widespread heat stress…

Humidity determines heat stress difference Humidity determines heat stress difference Apart from heat, humidity also determines the extent of heat stress felt by humans because it affects our ability to control our body temperature by sweating. InChina, while heat stress is recorded in different parts of the country in summer, the relatively humid weather in the south is believed to have resulted in more frequent occurrence of heat stress with severe health and economic impacts...
PR Newswire
11/06/2024

GN to gradually wind-down its Elite and Talk product lines. Strong performance…

As communicated at the Capital Market Day in May 2024, GN is striving to build leading businesses in attractive markets and by this grow with healthy margins and ensure good returns on the invested capital.The re-focusing of the Elite product line towards the premium segment, which was initiated in 2023, has resulted in a stronger profitability level than before. However, the investment required for future innovation and growth in this very competitive space is deemed unjustified in the...
Nasdaq GlobeNewswire
11/06/2024

Amber Implants Completes Enrolment of First-In-Human Clinical Trial of its…

The study enrolled 10 patients, all of whom suffered from severe disabling pain with Disability Ratings of 70% and higher. Following the procedure, typically lasting less than 20 minutes, all the patients saw maximal pain reduction with Disability Ratings reduced to 10% or less and they were able to walk freely without disability at discharge. The study enrolled 10 patients, all of whom suffered from severe disabling pain with Disability Ratings of 70% and higher. Following the procedure,...
PR Newswire
11/06/2024

Essential Pharma reaches agreement with AGC Biologics for late phase clinical…

Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastomaEgham, UK and Copenhagen, Denmark – 11 June, 2024– Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, today announced its rare disease business has...
Nasdaq GlobeNewswire
11/06/2024

Ultimovacs provides update from Phase I study in malignant melanoma: Continued…

All patients in the trial who were alive at 3 years remain alive at 4 years (69.5%) with a minimum follow-up period of 4 years (median 53.0 months)The expected next key milestone for UV1 is the readout of the FOCUS trial during Q3 2024, in which the treatment combination is the same as in the UV1-103 trialOslo, June 11, 2024:Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced encouraging overall...
Nasdaq GlobeNewswire
11/06/2024

NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis…

NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis PatientsAarhus, Denmark, 11 June 2024– NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, announces today that it has dosed the first generalized myasthenia gravis (gMG) patient in a Phase 2b clinical trial of NMD670, after receivingFDA IND clearance in March 2024to conduct the study. The first US patient...
Nasdaq GlobeNewswire
11/06/2024
Altri  Comunicati